Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01018186 · ClinicalTrials.gov registry record · Phase 3
Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 503
- Enrollment target
NCT01018186: Completed Phase 3 study, sponsored by GlaxoSmithKline.
NCT01018186 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 503 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01018186, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 503 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444
Primary Outcome
An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth de
Interventions
- DRUG Fluticasone propionate
- DRUG Fluticasone Furoate/GW642444
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 503 participants |
| Start Date | 2009-10-19 |
| Est. Completion | 2011-05-12 |
| Phase | Phase 3 |
What the finished NCT01018186 record still lists
NCT01018186 is an interventional study that assigns participants to a tested intervention. The registered 503 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 2 interventions - of which Fluticasone propionate is the first listed.
NCT01018186 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01018186 about?
NCT01018186 is a clinical study titled "Fluticasone Furoate/GW642444 Inhalation Powder Long-Term Safety Study". The purpose of this study is to evaluate the long-term safety of fluticasone furoate/GW642444
What is the current status of trial NCT01018186?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 503 participants. The study started on 2009-10-19. Estimated completion is 2011-05-12.
What interventions are being tested in trial NCT01018186?
The interventions under investigation include: Fluticasone propionate (DRUG), Fluticasone Furoate/GW642444 (DRUG).
Who is sponsoring clinical trial NCT01018186?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01018186's enrollment target sits among peer trials
503 743rd of 2000 higher than 1,258 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05143931 · 503 participants · NA
Avoid and Resist Strategies for Weight Management
- NCT05846282 · 504 participants · NA
Students Rising Above: Offsetting the Health and Mental Health Costs of Resilience
- NCT06072131 · 504 participants · Phase 3
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
- NCT06736522 · 504 participants · NA
Future Leaders Program: Testing a Youth Leadership, Engagement, and Mindfulness Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI